Cargando…

Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis

BACKGROUND: Previously, several studies investigated the effect of cladribine among patients with multiple sclerosis (MS) as a treatment option. Due to the contradictory results of previous studies regarding the efficacy and safety of cladribine in the MS population, we aimed to conduct a systematic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nabizadeh, Fardin, Mohamadi, Mobin, Rahmani, Shayan, Rajabi, Rayan, Afrashteh, Fatemeh, Najdaghi, Soroush, Mirmosayyeb, Omid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106322/ https://www.ncbi.nlm.nih.gov/pubmed/37062787 http://dx.doi.org/10.1007/s10072-023-06794-w

Ejemplares similares

Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Nabizadeh, Fardin, et al.
Publicado: (2022)

Psychometric Properties of the Persian Version of the Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ) Questionnaire
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review
por: Nabizadeh, Fardin, et al.
Publicado: (2022)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis
por: Alshamrani, Foziah, et al.
Publicado: (2020)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
por: Clavelou, Pierre, et al.
Publicado: (2023)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
por: Maltby, Vicki E, et al.
Publicado: (2021)

Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020)

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
por: Rejdak, Konrad, et al.
Publicado: (2021)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2019)

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update
por: Jack, Dominic, et al.
Publicado: (2021)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis
por: Rakers, Florian, et al.
Publicado: (2023)

Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
por: Petracca, Maria, et al.
Publicado: (2022)

Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Mirmosayyeb, Omid, et al.
Publicado: (2021)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Murphy, Julie A, et al.
Publicado: (2010)

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
por: Mao, Zhifeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3edscne0g79dhut6nsa5elsbo1